{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:38:00Z","timestamp":1793893080289,"version":"4.8.0"},"reference-count":131,"publisher":"SAGE Publications","issue":"4_suppl","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Arcutis Canada, Inc."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>\n                    Seborrheic dermatitis is a common chronic inflammatory skin condition that primarily affects areas with a high density of sebaceous glands, such as the scalp, face, central anterior trunk, and body folds. While the exact pathophysiology of seborrheic dermatitis is not fully understood, it is believed to involve a combination of microbial dysbiosis, immune imbalance, and skin barrier dysfunction. Effective management of seborrheic dermatitis includes treatments that reduce\n                    <jats:italic toggle=\"yes\">Malassezia<\/jats:italic>\n                    yeast colonization, control inflammation, normalize skin barrier dysfunction, and regulate sebum production. Topical therapies, including antifungals and anti-inflammatory agents such as corticosteroids and calcineurin inhibitors, are the mainstay of treatment of mild-to-moderate seborrheic dermatitis. Systemic therapies are reserved for severe or resistant seborrheic dermatitis cases. The recent development of new treatments, such as the topical phosphodiesterase-4 inhibitor (roflumilast 0.3% foam), shows promise in providing effective, noncorticosteroid options for seborrheic dermatitis management. This review provides an overview of current, as well as emerging therapeutic options, and discusses the importance of personalized treatment strategies in managing seborrheic dermatitis. This is the third in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.\n                  <\/jats:p>","DOI":"10.1177\/12034754251368824","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T12:21:10Z","timestamp":1758198070000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Current Understanding of Seborrheic Dermatitis: Treatment Options"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8654-9050","authenticated-orcid":false,"given":"Irina","family":"Turchin","sequence":"first","affiliation":[{"name":"Probity Medical Research Inc., Waterloo, ON, Canada"},{"name":"Brunswick Dermatology Centre, Fredericton, NB, Canada"},{"name":"Department of Medicine, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorne","family":"Albrecht","sequence":"additional","affiliation":[{"name":"Enverus Medical Research, University of British Columbia and Probity Medical Research, Surrey, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7712-7390","authenticated-orcid":false,"given":"Sameh","family":"Hanna","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc., Waterloo, ON, Canada"},{"name":"Dermatology on Bloor, Toronto, ON, Canada"},{"name":"Division of Dermatology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Kyritsis","sequence":"additional","affiliation":[{"name":"Clinique de Dermatologie Protoderma, Pierrefonds Medical Center, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Jing","family":"Loo","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc., Waterloo, ON, Canada"},{"name":"DermEffects, London, ON, Canada"},{"name":"Western University, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9163-5463","authenticated-orcid":false,"given":"Charles W.","family":"Lynde","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc., Waterloo, ON, Canada"},{"name":"Division of Dermatology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"Lynde Institute for Dermatology, Markham, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8315-2522","authenticated-orcid":false,"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc., Waterloo, ON, Canada"},{"name":"Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada"},{"name":"Sections of Community Pediatrics and Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, AB, Canada"},{"name":"Dermatology Research Institute, Calgary, AB, Canada"},{"name":"Skin Health &amp; Wellness Centre, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Purdy","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Rochette","sequence":"additional","affiliation":[{"name":"CHU de Quebec, L\u2019Ancienne-Lorette, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9634-3750","authenticated-orcid":false,"given":"Marni","family":"Wiseman","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc., Waterloo, ON, Canada"},{"name":"Section of Dermatology, Department of Medicine, University of Manitoba, Winnipeg, MB, Canada"},{"name":"SKiNWISE Dermatology, Winnipeg, MB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wong","sequence":"additional","affiliation":[{"name":"deRMA Skin Institute, Burlington, ON, Canada"},{"name":"Medcan, Oakville, ON, Canada"},{"name":"Division of Dermatology, Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9626-6863","authenticated-orcid":false,"given":"Geeta","family":"Yadav","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc., Waterloo, ON, Canada"},{"name":"Division of Dermatology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"FACET Dermatology, Toronto, ON, Canada"},{"name":"Division of Dermatology, Women\u2019s College Hospital, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, ON, Canada"},{"name":"Sunnybrook Health Sciences Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc., Waterloo, ON, Canada"},{"name":"SKiN Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada"},{"name":"Department of Medicine, Queen\u2019s University, Kingston, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"e_1_3_3_2_2","volume-title":"StatPearls","author":"Tucker D","year":"2025","unstructured":"Tucker D, Masood S. Seborrheic dermatitis. In: StatPearls [Internet]. StatPearls Publishing; 2025."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.13188\/2373-1044.1000019"},{"issue":"3","key":"e_1_3_3_4_2","first-page":"185","article-title":"Diagnosis and treatment of seborrheic dermatitis","volume":"91","author":"Clark GW","year":"2015","unstructured":"Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015;91(3):185-190.","journal-title":"Am Fam Physician"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14952"},{"issue":"2","key":"e_1_3_3_6_2","first-page":"44","article-title":"Optimizing treatment approaches in seborrheic dermatitis","volume":"6","author":"Goldenberg G","year":"2013","unstructured":"Goldenberg G. Optimizing treatment approaches in seborrheic dermatitis. J Clin Aesthet Dermatol. 2013;6(2):44-49.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14091"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.164410"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3661"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/cosmetics11060208"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S284671"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/12034754251368840"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/12034754251368828"},{"issue":"5","key":"e_1_3_3_14_2","first-page":"32","article-title":"Adult seborrheic dermatitis: a status report on practical topical management","volume":"4","author":"del Rosso JQ","year":"2011","unstructured":"del Rosso JQ. Adult seborrheic dermatitis: a status report on practical topical management. J Clin Aesthet Dermatol. 2011;4(5):32-38.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/J.1468-3083.2004.00693.x"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009446.pub2"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200708030-00003"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.09.031"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011380.pub2"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2017.1363"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1473554"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S303634"},{"key":"e_1_3_3_23_2","unstructured":"Arcutis Canada Inc. Zoryve Product Monograph. Health Canada Drug Product Database. Updated March 13 2025. Accessed July 8 2025. https:\/\/pdf.hres.ca\/dpd_pm\/00078853.PDF"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/J.jaad.2023.12.065"},{"key":"e_1_3_3_25_2","unstructured":"Health Canada. Drug product database. Published online. Accessed March 17 2025. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/drug-product-database.html"},{"key":"e_1_3_3_26_2","unstructured":"National Association of Pharmacy Regulatory Authorities (NAPRA). National Drug Schedules: ciclopirox or its salts. Accessed July 7 2025. https:\/\/www.napra.ca\/nds\/ciclopirox-or-its-salts\/"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01161-9"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/09546639909056025"},{"issue":"6","key":"e_1_3_3_29_2","first-page":"348","article-title":"Seborrheic dermatitis","volume":"35","author":"Berk T","year":"2010","unstructured":"Berk T, Scheinfeld N. Seborrheic dermatitis. P T. 2010;35(6):348-352.","journal-title":"P T"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008138.pub3"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/J.1365-2133.1989.TB01429.x"},{"issue":"7","key":"e_1_3_3_32_2","first-page":"646","article-title":"Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial","volume":"5","author":"Elewski B","year":"2006","unstructured":"Elewski B, Ling MR, Phillips TJ. Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial. J Drugs Dermatol. 2006;5(7):646-650.","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"e_1_3_3_33_2","first-page":"1001","article-title":"A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions","volume":"6","author":"Elewski BE","year":"2007","unstructured":"Elewski BE, Abramovits W, Kempers S, et al. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. J Drugs Dermatol. 2007;6(10):1001-1008.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00191"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0079"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14505"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00141.2016"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb08680.x"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200405060-00009"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200405060-00006"},{"key":"e_1_3_3_41_2","unstructured":"Beheshti Roy A Tavakoli-far B Fallah Huseini H Tousi P Shafigh N Rahimzadeh M. Efficacy of Melaleuca alternifolia essential oil in the treatment of facial seborrheic dermatitis: a double-blind randomized placebo-controlled clinical trial. J Med Plants. 2014;13(51):26-32. http:\/\/jmp.ir\/article-1-627-en.html"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/02681219780001451"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70282-x"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2023.4402"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1159\/000539209"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(90)70140-D"},{"issue":"1","key":"e_1_3_3_47_2","first-page":"26","article-title":"Scalp seborrheic dermatitis and dandruff therapy using a herbal and zinc pyrithione-based therapy of shampoo and scalp lotion","volume":"11","author":"Barak-Shinar D","year":"2018","unstructured":"Barak-Shinar D, Green LJ. Scalp seborrheic dermatitis and dandruff therapy using a herbal and zinc pyrithione-based therapy of shampoo and scalp lotion. J Clin Aesthet Dermatol. 2018;11(1):26-31.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22189730"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.15406\/jbmoa.2017.04.00076"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1997.tb00227.x"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/J.1365-2133.1986.TB04878.x"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.782092"},{"issue":"1","key":"e_1_3_3_53_2","first-page":"25","article-title":"Double blind study of sertaconazole 2% cream vs. clotrimazole 1% cream in treatment of seborrheic dermatitis","volume":"59","author":"Goldust M","year":"2013","unstructured":"Goldust M, Rezaee E, Rouhani S. Double blind study of sertaconazole 2% cream vs. clotrimazole 1% cream in treatment of seborrheic dermatitis. Ann Parasitol. 2013;59(1):25-29.","journal-title":"Ann Parasitol"},{"issue":"6","key":"e_1_3_3_54_2","first-page":"477","article-title":"Comparing the efficacy of Emu oil with clotrimazole and hydrocortisone in the treatment of seborrheic dermatitis: a clinical trial","volume":"18","author":"Attarzadeh Y","year":"2013","unstructured":"Attarzadeh Y, Asilian A, Shahmoradi Z, Adibi N. Comparing the efficacy of Emu oil with clotrimazole and hydrocortisone in the treatment of seborrheic dermatitis: a clinical trial. J Res Med Sci. 2013;18(6):477-481.","journal-title":"J Res Med Sci"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.3390\/JPM12091540"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.806765"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2005.tb00708.x"},{"issue":"7","key":"e_1_3_3_58_2","first-page":"4","article-title":"Ciclopirox (Loprox) gel for superficial fungal infections","volume":"9","author":"Gupta AK","year":"2004","unstructured":"Gupta AK, Bluhm R. Ciclopirox (Loprox) gel for superficial fungal infections. Skin Therapy Lett. 2004;9(7):4-9.","journal-title":"Skin Therapy Lett"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/J.1365-4632.2004.02331.x"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04194.x"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.42.s1.5.x"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1159\/000076478"},{"issue":"1","key":"e_1_3_3_63_2","first-page":"125","article-title":"Seborrheic dermatitis: an overview","volume":"74","author":"Schwartz RA","year":"2006","unstructured":"Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician. 2006;74(1):125-130.","journal-title":"Am Fam Physician"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0806464"},{"issue":"9","key":"e_1_3_3_65_2","first-page":"2703","article-title":"Treatment of seborrheic dermatitis","volume":"61","author":"Johnson BA","year":"2000","unstructured":"Johnson BA, Nunley JR. Treatment of seborrheic dermatitis. Am Fam Physician. 2000;61(9):2703-2714.","journal-title":"Am Fam Physician"},{"issue":"6","key":"e_1_3_3_66_2","first-page":"337","article-title":"Topical corticosteroids: choice and application","volume":"103","author":"Stacey SK","year":"2021","unstructured":"Stacey SK, McEleney M. Topical corticosteroids: choice and application. Am Fam Physician. 2021;103(6):337-343.","journal-title":"Am Fam Physician"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2016.11.008"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(88)70244-3"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.02.032"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1111\/J.1365-2133.2004.06208.x"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1159\/000247566"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1177\/1721727X0300100207"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2009.09.002"},{"issue":"5","key":"e_1_3_3_74_2","first-page":"397","article-title":"Clobetasol propionate shampoo 0.05% in the treatment of seborrheic dermatitis of the scalp: results of a pilot study","volume":"79","author":"Reygagne P","year":"2007","unstructured":"Reygagne P, Poncet M, Sidou F, Soto P. Clobetasol propionate shampoo 0.05% in the treatment of seborrheic dermatitis of the scalp: results of a pilot study. Cutis. 2007;79(5):397-403. PMID: 17569404","journal-title":"Cutis"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05383.x"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00687-06"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01752-17"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1007\/S40257-016-0232-2"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1532"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1586\/ECP.11.68"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.2165\/11311160-000000000-00000"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2015.27.5.523"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.11.007"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.8.1066"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.450"},{"issue":"2","key":"e_1_3_3_86_2","first-page":"73","article-title":"Treatment of seborrheic dermatitis: the efficiency of sertaconazole 2% cream vs. tacrolimus 0.03% cream","volume":"59","author":"Goldust M","year":"2013","unstructured":"Goldust M, Rezaee E, Raghifar R, Hemayat S. Treatment of seborrheic dermatitis: the efficiency of sertaconazole 2% cream vs. tacrolimus 0.03% cream. Ann Parasitol. 2013;59(2):73-77.","journal-title":"Ann Parasitol"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2011.10080"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S101233"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.12.017"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1177\/1203475420909794"},{"issue":"5","key":"e_1_3_3_91_2","first-page":"577","article-title":"Chronic nasolabial fold seborrheic dermatitis successfully controlled with crisaborole","volume":"17","author":"Liu D","year":"2018","unstructured":"Liu D, Chow P, Strawn S, Rajpara A, Wang T, Aires D. Chronic nasolabial fold seborrheic dermatitis successfully controlled with crisaborole. J Drugs Dermatol. 2018;17(5):577-578. PMID: 29742192","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1177\/1203475419878162"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16673"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.4990"},{"key":"e_1_3_3_95_2","unstructured":"ClinicalTrials.gov. PDE4 inhibition in seborrheic dermatitis and papulopustular rosacea. Accessed August 1 2024. https:\/\/clinicaltrials.gov\/study\/NCT06013371"},{"key":"e_1_3_3_96_2","unstructured":"Government of Canada. Notice of compliance information\u2014LOPROX. November 25 2022. Accessed December 15 2024. https:\/\/health-products.canada.ca\/noc-ac\/nocInfo?no=4314"},{"key":"e_1_3_3_97_2","unstructured":"Andrus E. Health Canada approves roflumilast foam 0.3% for patients 9 years and older with seborrheic dermatitis. Dermatology Times. October 18 2024. Accessed December 15 2024. https:\/\/www.dermatologytimes.com\/view\/health-canada-approves-roflumilast-foam-0-3-for-patients-9-years-and-older-with-seborrheic-dermatitis"},{"issue":"5","key":"e_1_3_3_98_2","first-page":"30","article-title":"Putting the formulation back in foam: optimizing seborrheic dermatitis treatment across diverse hair types","volume":"17","author":"Chovatiya R","year":"2024","unstructured":"Chovatiya R, Polaskey MT, Lain E, et al. Putting the formulation back in foam: optimizing seborrheic dermatitis treatment across diverse hair types. J Clin Aesthet Dermatol. 2024;17(5):30-33.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.232819"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.25251\/skin.8.5.20"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1136"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.0846"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00741-9"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.05.602"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.2340\/ACTADV.V103.12343"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.04.003"},{"key":"e_1_3_3_107_2","unstructured":"ClinicalTrials.gov. Ruxolitinib in seborrheic dermatitis. Accessed August 1 2024. https:\/\/clinicaltrials.gov\/study\/NCT05787860"},{"key":"e_1_3_3_108_2","unstructured":"Incyte Corporation. Opzelura Product Monograph. Health Canada Drug Product Database. Updated October 11 2024. Accessed March 16 2025. https:\/\/pdf.hres.ca\/dpd_pm\/00077370.PDF"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0119-4"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1675855"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12197"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70483-9"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01090.x"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200708040-00005"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809002400914"},{"key":"e_1_3_3_116_2","doi-asserted-by":"publisher","DOI":"10.15218\/zjms.2018.054"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.010"},{"key":"e_1_3_3_118_2","volume-title":"StatPearls","author":"Pile HD","year":"2025","unstructured":"Pile HD, Patel P, Sadiq NM. Isotretinoin. In: StatPearls [Internet]. StatPearls Publishing; 2025."},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.87137"},{"key":"e_1_3_3_120_2","doi-asserted-by":"publisher","DOI":"10.1177\/039463200501800418"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2390644"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0151-9638(06)70941-3"},{"key":"e_1_3_3_123_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bdj.4800461"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(72)80218-x"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.50.11.871"},{"key":"e_1_3_3_126_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1976.tb140871.x"},{"issue":"5","key":"e_1_3_3_127_2","first-page":"370","article-title":"Biotin interference: underrecognized patient safety risk in laboratory testing","volume":"64","author":"Gifford JL","year":"2018","unstructured":"Gifford JL, Sadrzadeh SMH, Naugler C. Biotin interference: underrecognized patient safety risk in laboratory testing. Can Fam Physician. 2018;64(5):370.","journal-title":"Can Fam Physician"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.3390\/cosmetics12010003"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53016-0"},{"key":"e_1_3_3_130_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14030557"},{"key":"e_1_3_3_131_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.122734"},{"key":"e_1_3_3_132_2","doi-asserted-by":"publisher","DOI":"10.1159\/000211450"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754251368824","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/12034754251368824","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754251368824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:52:17Z","timestamp":1777391537000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/12034754251368824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":131,"journal-issue":{"issue":"4_suppl","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/12034754251368824"],"URL":"https:\/\/doi.org\/10.1177\/12034754251368824","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]}}}